Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Collaborative work unravels hidden molecular secrets of age-related diseases

Collaborative work unravels hidden molecular secrets of age-related diseases

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

ASU scientists discover an unusual RNA biogenesis pathway

ASU scientists discover an unusual RNA biogenesis pathway

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

New white paper outlines the issues surrounding delays in diagnosing interstitial lung diseases

New white paper outlines the issues surrounding delays in diagnosing interstitial lung diseases

CD98 identified as a key mediator of pro-fibrotic and acute inflammatory responses in the lung

CD98 identified as a key mediator of pro-fibrotic and acute inflammatory responses in the lung

How can we map the human genetic architecture of COVID-19 across all ancestry groups?

How can we map the human genetic architecture of COVID-19 across all ancestry groups?

New AI algorithm accurately and quickly diagnoses idiopathic pulmonary fibrosis

New AI algorithm accurately and quickly diagnoses idiopathic pulmonary fibrosis

Study offers insight into the basic cellular pathologies driving interstitial lung disease

Study offers insight into the basic cellular pathologies driving interstitial lung disease

Y chromosome loss in men can lead to deadly heart failure, research shows

Y chromosome loss in men can lead to deadly heart failure, research shows

Novel inhalable COVID-19 vaccine

Novel inhalable COVID-19 vaccine

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Zinc may reverse lung damage, improve survival for patients with idiopathic pulmonary fibrosis

Zinc may reverse lung damage, improve survival for patients with idiopathic pulmonary fibrosis

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation